证券代码：002873 证券简称：新天药业 公告编号：2025-053 根据《深圳证券交易所股票上市规则》、《公司章程》等相关规定，本次对 外投资金额未达到董事会或股东会的审议标准，无需提交董事会和股东会审议。 本次投资事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 | 名称 | 贵州中道中医药健康科技有限公司 | | --- | --- | | 统一社会信用代码 | 91520112MAEURRW39J | | 类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 住所 | 贵州省贵阳市乌当区新创路街道新添大道 号 114 | | 法定代表人 | 魏茂陈 | 二、设立全资子公司的基本情况 贵阳新天药业股份有限公司 关于对外投资设立全资子公司并完成 工商注册登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 贵阳新天药业股份有限公司（以下简称"公司"）为进一步加大综合性医药 产业布局，加快实现保健食品研发与成果转化，完善公司多元化产品矩阵，促进 市场销售规模提升，公司以自有资金人民币 ...

Core Viewpoint - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its product matrix and overall profitability [1] Group 1: Investment Details - The investment amount is 10 million RMB, aimed at promoting the research and development of health food and its transformation into products [1] - The registered capital of Zhongdao Health is exactly 10 million RMB, with Wei Maochen as the legal representative [1] - The establishment date of the subsidiary is September 1, 2025, and it has received a business license from the Market Supervision Administration of Wudang District, Guiyang City [1] Group 2: Business Scope - The business scope of the new subsidiary includes the production of health food, special medical purpose formula food, infant formula food, food additives, dairy products, beverages, and food sales [1] - This diversification aims to enhance the company's overall profitability and risk resistance [1] - The investment aligns with the company's strategic goal of becoming a comprehensive pharmaceutical enterprise [1]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction, which enhances its intellectual property protection and strengthens its core competitiveness through technological innovation [1][2]. Summary by Sections Patent Details - The patent is titled "A Method for Detecting the Fingerprint Spectrum of Ginkgo Biloba Decoction" with certificate number 8210031 [1]. - The patent was granted to Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company [1]. - The patent application was filed on June 19, 2023, and the authorization announcement date is August 29, 2025 [1]. Technological Significance - The patented technology allows for comprehensive detection of the types and quantities of chemical components in ginkgo biloba, establishing a fingerprint spectrum method [1]. - This method will provide a basis for the use of high-quality medicinal materials in product production, ensuring product quality [1]. Impact on Company Operations - The acquisition of this patent is not expected to have a significant impact on the company's production and operations but will enhance the company's intellectual property protection system [2]. - The technology is anticipated to be utilized in the production of new drug products, improving the stability and effectiveness of the company's offerings [1][2].

证券代码：002873 证券简称：新天药业 公告编号：2025-052 贵阳新天药业股份有限公司 关于取得发明专利证书的公告 专利号：ZL 2023 1 0723330.2 授权公告号：CN 116718700 B 专利申请日：2023 年 06 月 19 日 授权公告日：2025 年 08 月 29 日 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）的全资子公司上海硕方医 药科技有限公司于近日收到国家知识产权局颁发的一项发明专利证书，具体情况 如下： 发明专利名称：一种检测白果水煎液指纹图谱的方法及其指纹图谱 证书号：第 8210031 号 发明名称：一种检测白果水煎液指纹图谱的方法及其指纹图谱 专利权人：上海硕方医药科技有限公司 地址：201499 上海市奉贤区望园路 1888 号 1 幢 5 层 发明人：韩豫；王亚茹；成亮；魏茂陈 董事会 2025 年 9 月 3 日 2 申请日时申请人：上海硕方医药科技有限公司 申请日时发明人：韩豫；王亚茹；成亮；魏茂陈 上述发明专利为公司自主技术创新，"一种检测白果水煎液 ...

Market Overview - The Chinese medicine sector experienced a decline of 1.31% on September 3, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Xiangxue: Closed at 10.93, up 2.44% with a trading volume of 268,100 shares [1] - Guizhou Sanli: Closed at 12.80, up 1.43% with a trading volume of 84,000 shares [1] - Weikang Pharmaceutical: Closed at 22.99, up 1.10% with a trading volume of 78,800 shares [1] - Significant decliners included: - Xinda Pharmaceutical: Closed at 11.53, down 5.72% with a trading volume of 156,000 shares [2] - Zhendong Pharmaceutical: Closed at 8.21, down 4.53% with a trading volume of 675,200 shares [2] - Tailong Pharmaceutical: Closed at 6.72, down 4.00% with a trading volume of 294,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 829 million yuan from institutional investors, while retail investors contributed a net inflow of 679 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Guizhou Sanli had a net inflow of 17.47 million yuan from institutional investors, but a net outflow of 13.66 million yuan from retail investors [3] - Weikang Pharmaceutical experienced a net inflow of 8.62 million yuan from institutional investors, while retail investors withdrew 9.30 million yuan [3] - Other notable stocks with significant capital movements include: - ST Xiangxue: Net inflow of 2.50 million yuan from institutional investors [3] - Yunnan Baiyao: Net inflow of 2.27 million yuan from institutional investors [3]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., has received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction, which will enhance the company's intellectual property protection and core competitiveness [1] Summary by Relevant Categories Patent Information - The patent certificate (No. 8210031) was issued by the National Intellectual Property Administration, with the application date on June 19, 2023, and the authorization announcement date set for August 29, 2025 [1] Product Quality Assurance - The patented method allows for comprehensive detection of the chemical components of ginkgo biloba, providing a basis for ensuring product quality, which will be utilized in the production of related new drugs [1] Impact on Company Operations - While the patent does not have a significant immediate impact on the company's production and operations, it contributes positively to the enhancement of the intellectual property protection system [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on August 28, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Buchang Pharmaceutical (603858) with a closing price of 20.02, up 5.59% and a trading volume of 325,000 shares, totaling 654 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 20.40, up 5.37% with a trading volume of 159,300 shares, totaling 324 million yuan [1] - Jilin Aodong (000623) closed at 20.34, up 1.75% with a trading volume of 239,000 shares, totaling 479 million yuan [1] - Conversely, significant decliners included: - Xinda Pharmaceutical (002873) with a closing price of 12.00, down 4.76% and a trading volume of 304,000 shares, totaling 364 million yuan [2] - Qidi Pharmaceutical (000590) closed at 12.22, down 4.61% with a trading volume of 221,600 shares, totaling 274 million yuan [2] - Kangjia Pharmaceutical (600557) closed at 17.22, down 4.39% with a trading volume of 313,700 shares, totaling 537 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors contributed a net inflow of 930 million yuan [2] - Key stocks with significant capital flow included: - Zhendong Pharmaceutical (300158) with a net inflow of 67.58 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 13.62 million yuan from institutional investors [3] - Tianmu Pharmaceutical (600671) with a net inflow of 7.33 million yuan from institutional investors [3]

Group 1 - The stock price of Xintian Pharmaceutical is reported at 12.81 yuan, down 0.50 yuan or 3.76% from the previous trading day [1] - The stock reached a high of 13.47 yuan and a low of 12.78 yuan during the trading session, with a trading volume of 391,500 hands and a transaction amount of 508 million yuan [1] - Xintian Pharmaceutical operates in the traditional Chinese medicine industry, focusing on the research, development, production, and sales of traditional Chinese medicine and chemical drugs [1] Group 2 - On August 26, the company hosted a research meeting with several institutions, including Morgan Stanley Fund and Caitong Fund, discussing the progress of its research pipeline [1] - The research information indicates that the company has made progress in the development of modified new drugs for tumor adjuvant therapy [1] - On August 26, the net outflow of main funds from Xintian Pharmaceutical was 66.77 million yuan, accounting for 2.18% of the circulating market value [1] Group 3 - Over the past five trading days, the cumulative net outflow of main funds reached 137 million yuan, representing 4.47% of the circulating market value [1]

Report Summary 1. Report Industry Investment Rating No relevant information provided. 2. Core Views of the Report - The company has made progress in R & D pipelines, including in the fields of oncology, cardiovascular and cerebrovascular diseases, gynecology and pain, and urinary system diseases [19]. - The company has achieved breakthroughs in the secondary development of listed products, such as the multiple effects of Kuntai Capsules, the high - level evaluation of Kushen Gel and Ningmitai Capsules [20][21]. - The company increased investment in Huilun Pharmaceutical due to its innovation ability, R & D achievements, and commercialization capabilities [22][23]. - The company's main products are currently not affected by the centralized procurement policy, and it will take measures to deal with potential impacts [24]. - The company's short - term business performance decline is affected by raw material price increases, R & D investment, etc., and it will take corresponding measures to deal with it [25][26]. - The company believes that traditional Chinese medicine innovation is an important part of the development of the pharmaceutical industry and will balance short - and long - term R & D investment [26][28]. 3. Summary According to the Directory 3.1 Research Basic Situation - Research object: Xintian Pharmaceutical - Industry: Traditional Chinese medicine - Reception time: August 26, 2025 - Reception personnel: Wang Guangping (Director, Deputy General Manager, Secretary of the Board of Directors), Liang Yongsong (Securities Manager) [16] 3.2 Detailed Research Institutions - Fund management companies: Morgan Stanley Fund, Caitong Fund, Guohai Franklin Fund, Morgan Fund, Zhongou Fund - Other types: Xianghe Investment, Ruiyi Investment - Securities companies: Orient Securities Self - operation, Hua'an Securities, Zhongyou Securities [17] 3.3 Research Institution Proportion No relevant information provided. 3.4 Main Content Data - **R & D pipelines**: In the oncology field, a 2.3 - class improved new drug submitted an IND application in July 2025; in the cardiovascular and cerebrovascular field, two 1.1 - class traditional Chinese medicine innovative drugs are in the process of process research; in the gynecology and pain field, classic famous prescriptions are preparing for NDA application; in the urinary system diseases field, a 1.1 - class traditional Chinese medicine innovative drug project is being advanced [19]. - **Secondary development of listed products**: Kuntai Capsules have multiple effects on perimenopausal syndrome and reproductive health; Kushen Gel was rated as Class A in clinical value and won a science and technology progress award; Ningmitai Capsules were certified as Class A in clinical comprehensive evaluation and are undergoing a multi - center clinical trial [20][21]. - **Investment in Huilun Pharmaceutical**: Huilun Pharmaceutical has a strong R & D system and commercialization experience. The company increased its investment in Huilun Pharmaceutical by 40 million yuan in August 2025 [22][23]. - **Centralized procurement policy**: The company's main products are currently not affected by the centralized procurement policy. It will increase OTC market investment and control costs [24]. - **Business performance**: The decline in business performance is affected by raw material price increases and R & D investment. The company will adjust marketing strategies and manage raw material procurement [25][26]. - **Innovation drug strategy**: Traditional Chinese medicine innovation is an important part of the company's development. The company will balance short - and long - term R & D investment [26][28].

Group 1 - The core viewpoint of the article is that Xintian Pharmaceutical (SZ 002873) has engaged with investors through a research meeting, indicating active investor relations and transparency [1] - For the first half of 2025, Xintian Pharmaceutical reported that its main revenue accounted for 99.9% of total revenue, with other business activities contributing only 0.1% [1] - As of the report date, Xintian Pharmaceutical has a market capitalization of 3.1 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to positive performance among listed companies in this sector [1]